Fennec Pharmaceuticals Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; U.S. dollars unless stated otherwise. The filing was signed March 29, 2024. Q4 figures are included where disclosed.
Business context
Fennec is a commercial-stage, single-product biopharmaceutical company. PEDMARK (sodium thiosulfate injection) is FDA-approved to reduce cisplatin-associated hearing-loss risk in pediatric patients with localized, non-metastatic solid tumors. U.S. sales began in October 2022. PEDMARQSI, the European brand, received European Commission authorization and PUMA pediatric exclusivity in 2023; U.K. approval followed in October 2023.
Financial results and liquidity
| Metric (USD millions, except per-share data) | FY2023 | FY2022 |
|---|---|---|
| Net product sales | $21.252 | $1.535 |
| Cost of products sold | $1.259 | $0.086 |
| Gross profit / gross margin | $19.993 / 94.1% | $1.449 / 94.4% |
| Operating expenses | $32.764 | $24.038 |
| Operating loss | $12.771 | $22.589 |
| Net loss | $16.045 | $23.714 |
| Basic and diluted loss per share | $0.60 | $0.90 |
| Cash used in operating activities | $17.143 | $18.058 |
| Cash and cash equivalents at year-end | $13.269 | $23.774 |
Q4 2023 net sales were $9.735 million, gross profit $9.050 million, operating loss $1.818 million and net loss $2.682 million. Q4 2022 net sales were $1.535 million and net loss $6.857 million.
At December 31, 2023, current assets were $26.858 million, current liabilities $7.553 million and working capital $19.305 million. Accounts receivable was $8.814 million and inventory $2.156 million. Total liabilities were $38.486 million, including a $30.0 million term loan principal balance and $1.219 million accrued PIK interest. Shareholders’ deficit was $11.622 million. Cash declined $10.505 million during 2023; financing activities provided $6.638 million. The filing reports no material off-balance-sheet arrangements.
Changes versus the prior period
- Net sales rose substantially as the U.S. launch scaled; reported net product revenue increased by $19.717 million year over year.
- Operating loss narrowed by $9.818 million and net loss by $7.669 million, despite higher commercial and administrative spending.
- Research and development expense fell to $0.056 million from $3.531 million as the company shifted from development toward commercialization.
- Selling and marketing expense increased to $12.123 million from $2.785 million, primarily reflecting launch-related staffing, marketing and distribution costs. General and administrative expense rose to $20.585 million from $17.722 million.
- Interest expense increased to $3.394 million from $0.978 million, mainly due to higher average debt and interest rates. Cash fell year over year, while working capital decreased by $2.815 million.
Outlook, risks and unusual items
- Norgine agreement, subsequent event: In March 2024, Fennec announced an exclusive license for Norgine to commercialize PEDMARQSI in Europe, Australia and New Zealand. Fennec received approximately $43 million upfront, with potential additional commercial and regulatory milestones and royalties; the filing cites approximately $230 million in potential future payments. This post-year-end transaction was not FY2023 product revenue or year-end cash.
- Liquidity outlook: Management stated that available resources were expected to fund operations for at least 12 months, citing year-end cash, expected product-sales collections, a remaining $15 million under the Petrichor facility subject to mutual agreement, and the subsequent Norgine payment. The company continued to report operating losses and negative operating cash flow.
- Debt: The $30 million Petrichor notes are secured by company and subsidiary assets, mature in 2027, and bear cash interest at prime plus 4.5% (11% at year-end) plus 3.5% PIK interest, which stops accruing in August 2024. Further draws are subject to mutual agreement. Default or change-of-control provisions can accelerate repayment.
- Accounting and controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end because of a material weakness in accounting for distributor fees and allowances, including measurement, classification and timing of distinct services. Remediation was underway but not yet fully implemented and tested. The company revised its previously reported September 2023 results: net product sales decreased $0.219 million, selling and marketing expense decreased $1.169 million, and current assets increased $0.950 million.
- Revenue estimation: FY2023 discounts and allowances were $2.530 million. The auditor identified estimated product allowances and distributor-service valuation and timing as a critical audit matter. The filing also reports $6.3 million of distinct distributor services, including $2.0 million recorded as prepaid expense at year-end.
- Competition and intellectual property: CIPLA’s generic-drug application challenged listed patents, and related infringement litigation remained ongoing. The PTAB invalidated the sole claim of the OHSU-licensed ’190 patent; Fennec requested its removal from the Orange Book. The company also faces competition from lower-cost compounded sodium thiosulfate, as well as payer coverage, reimbursement and pricing risks.
- Other key risks: Fennec relies on contract manufacturers and distributors, has a small target patient population, and depends on continued market acceptance, adequate reimbursement and sufficient supply. It has a history of losses and may need additional financing. Money-market balances exceeded FDIC-insured limits. The audited financial statements received an unqualified opinion; the auditor did not opine on internal-control effectiveness.
Important facts for investors to verify
- Commercial uptake, net realized pricing, patient access, payer coverage and the assumptions behind product-sales allowances.
- Whether distributor-service costs and prepaid balances are correctly measured and recognized, and whether the disclosed control weakness is remediated and tested.
- Timing and terms of Norgine milestones and royalties, and whether the remaining Petrichor financing is available when needed.
- Debt interest, security, conversion provisions and maturity; assess cash runway using operating cash burn and exclude contingent financing until committed.
- Status and potential outcome of the CIPLA litigation, remaining patent protections, and risk from compounding or generic competition.
- Current cash, receivable collections, inventory recoverability and the company’s path to positive operating cash flow.